Changes in Beneficial Ownership · 4
Rapid Micro Biosystems, Inc.
RPIDNASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
wk-form4_1780443754.xml
Filing details
- Report period
- 2026-05-29
- Issuer
- RAPID MICRO BIOSYSTEMS, INC.
- Issuer CIK
- 0001380106
- Trading symbol
- RPID
Reporting owner 1
- Name
- Malloy Kirk
- Reporting owner CIK
- 0001326794
- Relationship
- Director
- Address
- C/O RAPID MICRO BIOSYSTEMS, INC., 25 HARTWELL AVENUE, LEXINGTON, MA, 02421
Non-derivative transactions
| Security | Transaction date | Code | Amount | A / D | Price (USD) | Owned after | Ownership |
|---|---|---|---|---|---|---|---|
| Class A Common Stock | 2026-05-29 | A · Form 4[F1] | 12,787 | A | 1.955 | 60,687 | D |
Table key
- A · Form 4
- Acquisition by grant, award or otherwise under Rule 16b-3(d)
- A
- Acquired
- D
- Direct
Non-derivative holdings
| Security | Amount owned | Ownership | Nature of ownership |
|---|---|---|---|
| Class A Common Stock | 10,000 | I | By Trust[F2] |
Table key
- I
- Indirect
Derivative transactions
| Security | Conversion / exercise price (USD) | Transaction date | Code | Amount | A / D | Price (USD) | Exercisable | Expires | Underlying security | Underlying shares | Owned after | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Series A Warrant (right to buy) | 1.955 | 2026-05-29 | A · Form 4[F1] | 12,787 | A | 0[F1] | 2026-11-29[F3] | 2027-05-29 | Class A Common Stock | 12,787 | 12,787 | D |
| Series B Warrant (right to buy) | 2.34 | 2026-05-29 | A · Form 4[F1] | 12,787 | A | 0[F1] | 2026-11-29[F3] | 2031-05-29 | Class A Common Stock | 12,787 | 12,787 | D |
Table key
- A · Form 4
- Acquisition by grant, award or otherwise under Rule 16b-3(d)
- A
- Acquired
- D
- Direct
Footnotes
- F1
- On May 29, 2026, the Reporting Person purchased, in a registered direct offering, 12,787 shares of the Issuer's Class A Common Stock, as well as an accompanying Series A Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof) and an accompanying Series B Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof). The purchase price of each share of Issuer Class A Common Stock and accompanying Series A and Series B Warrant was $1.955. The issuance of such securities was approved by the Issuer's compensation committee of the board of directors in accordance with Rule 16(b)-3 of the Securities Exchange Act of 1934, as amended.↩ 1↩ 2↩ 3↩ 4↩ 5
- F2
- Shares held in family trust as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries.↩ 1
- F3
- The Series A and Series B Warrants cannot be exercised for shares of the Issuer's Class A Common Stock if, as a result of such exercise, the holder, together with its affiliates and any other persons whose beneficial ownership would be aggregated for purposes of Section 13(d) of the Act, would beneficially own more than 4.99% of the total number of shares of the Issuer's Class A Common Stock then outstanding immediately following such exercise.↩ 1↩ 2
Signature 1
- Signed
- /s/ Sean M. Wirtjes, Attorney-in-Fact for Kirk Malloy
- Date
- 2026-06-02
Company context
Rapid Micro Biosystems is an innovative life sciences technology company providing mission-critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The Company’s flagship Growth Direct system automates and modernizes the antiquated, manual microbial quality control (“MQC”) testing workflows used in the largest and most complex pharmaceutical manufacturing operations across the globe. The Growth Direct system brings the quality control lab to the manufacturing floor, unlocking the power of MQC automation to deliver the faster results, greater accuracy, increased operational efficiency, better compliance with data integrity regulations, and quicker decision making that customers rely on to ensure safe and consistent supply of important healthcare products. The Company is headquartered in Lexington, Massachusetts and has U.S. manufacturing in Lowell, Massachusetts, with global locations in Switzerland, Germany, and the Netherlands. For more information, please visit www.rapidmicrobio.com or follow the Company on X (formerly known as Twitter) at @rapidmicrobio or on LinkedIn.
Current securities
Recent company filings
- 10-Q filingNov 19, 2026
- SC14D9C - filed by RAPID MICRO BIOSYSTEMS, INC. regarding RAPID MICRO BIOSYSTEMS, INC.Nov 17, 2026
- NT 10-Q filingNov 16, 2026
- SC14D9C - filed by RAPID MICRO BIOSYSTEMS, INC. regarding RAPID MICRO BIOSYSTEMS, INC.Nov 16, 2026
- Entry into a Material Definitive Agreement · Other EventsNov 16, 2026